Chihiro Morishima

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C
    C Morishima
    Division of Virology, Department of Laboratory Medicine, University of Washington, Seattle, WA 98109, USA
    J Viral Hepat 19:404-13. 2012
  2. ncbi request reprint Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV coinfection
    Chihiro Morishima
    Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
    J Infect Dis 196:577-86. 2007
  3. ncbi request reprint HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial
    Chihiro Morishima
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98104, USA
    Hepatology 44:360-7. 2006
  4. ncbi request reprint Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C
    Chihiro Morishima
    Department of Laboratory Medicine and Pediatrics, University of Washington, Seattle, USA
    J Infect Dis 193:931-40. 2006
  5. ncbi request reprint Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing
    Chihiro Morishima
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
    Hepatology 43:573-80. 2006
  6. pmc Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection
    Chihiro Morishima
    Division of Virology, Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington 98104, USA
    Gastroenterology 138:671-81, 681.e1-2. 2010
  7. pmc Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C
    Chihiro Morishima
    Department of Laboratory Medicine, Virology Division, University of Washington, Seattle, WA, USA
    Hepatology 48:1412-9. 2008
  8. pmc Identification of hepatoprotective flavonolignans from silymarin
    Stephen J Polyak
    Department of Laboratory Medicine, Microbiology and Global Health, University of Washington, Seattle, WA 98104, USA
    Proc Natl Acad Sci U S A 107:5995-9. 2010
  9. ncbi request reprint Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin
    Stephen J Polyak
    Department of Laboratory Medicine, University of Washington, Seattle, Washington 98104 2499, USA
    Gastroenterology 132:1925-36. 2007
  10. pmc Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis
    Stephen J Polyak
    Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
    Virol J 2:41. 2005

Research Grants

Collaborators

Detail Information

Publications27

  1. pmc Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C
    C Morishima
    Division of Virology, Department of Laboratory Medicine, University of Washington, Seattle, WA 98109, USA
    J Viral Hepat 19:404-13. 2012
    ..009). Poorer CD4+ T cell proliferative function was associated with more advanced liver disease in chronic hepatitis C and may be further affected by long-term PEG-IFN treatment...
  2. ncbi request reprint Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV coinfection
    Chihiro Morishima
    Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
    J Infect Dis 196:577-86. 2007
    ..Human immunodeficiency virus (HIV) coinfection and low peripheral blood CD4(+) T cell counts are associated with increased hepatitis C liver disease...
  3. ncbi request reprint HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial
    Chihiro Morishima
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98104, USA
    Hepatology 44:360-7. 2006
    ..In patients with negative PCR results during treatment, a single positive TMA test did not exclude SVR, although persistently positive tests did...
  4. ncbi request reprint Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C
    Chihiro Morishima
    Department of Laboratory Medicine and Pediatrics, University of Washington, Seattle, USA
    J Infect Dis 193:931-40. 2006
    ..Thus, in patients with advanced hepatic fibrosis due to HCV infection, pretreatment HCV-specific immune responses and increased QS variability appear to hinder viral clearance by pegylated IFN- alpha 2a and ribavirin combination therapy...
  5. ncbi request reprint Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing
    Chihiro Morishima
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
    Hepatology 43:573-80. 2006
    ..035). In conclusion, NK cell cytolytic function does not appear to be impaired in chronic hepatitis C, but higher levels of NK cell cytolysis are associated with less liver fibrosis...
  6. pmc Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection
    Chihiro Morishima
    Division of Virology, Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington 98104, USA
    Gastroenterology 138:671-81, 681.e1-2. 2010
    ..The goal of this study was to determine whether silymarin has in vitro effects on immune function that might have implications for its potential effect on hepatitis C virus (HCV)-induced liver disease...
  7. pmc Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C
    Chihiro Morishima
    Department of Laboratory Medicine, Virology Division, University of Washington, Seattle, WA, USA
    Hepatology 48:1412-9. 2008
    ..With continued treatment, patients with inconsistently positive TMA results were more likely to become TMA-negative than TMA-positive (P < 0.0001)...
  8. pmc Identification of hepatoprotective flavonolignans from silymarin
    Stephen J Polyak
    Department of Laboratory Medicine, Microbiology and Global Health, University of Washington, Seattle, WA 98104, USA
    Proc Natl Acad Sci U S A 107:5995-9. 2010
    ..The data suggest that silymarin- and silymarin-derived compounds may influence HCV disease course in some patients. Studies where standardized silymarin is dosed to identify specific clinical endpoints are urgently needed...
  9. ncbi request reprint Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin
    Stephen J Polyak
    Department of Laboratory Medicine, University of Washington, Seattle, Washington 98104 2499, USA
    Gastroenterology 132:1925-36. 2007
    ..Milk thistle's clinical benefits for chronic hepatitis C are unsettled due to variability in standardization of the herbal product...
  10. pmc Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis
    Stephen J Polyak
    Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
    Virol J 2:41. 2005
    ..QS diversity and complexity were quantified using heteroduplex mobility assays (HMA)...
  11. ncbi request reprint Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy
    Chihiro Morishima
    University of Washington, School of Medicine, Seattle, WA 98195, USA
    Clin Immunol 108:211-20. 2003
    ....
  12. ncbi request reprint High serum hepatitis C virus (HCV) RNA load predicts the presence of HCV RNA in saliva from individuals with chronic and acute HCV infection
    Chia C Wang
    Department of Medicine, University of Washington, Seattle 98104 2499, USA
    J Infect Dis 193:672-6. 2006
    ..This association was also observed in 1 subject with acute HCV infection. Thus, our data demonstrate that salivary HCV RNA detection was associated with serum HCV RNA load in individuals who were chronically or acutely infected with HCV...
  13. ncbi request reprint Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia
    Mark H Wener
    Department of Laboratory Medicine, University of Washington, Seattle 98195, USA
    Arthritis Rheum 50:2305-8. 2004
    ..To determine if antibodies to cyclic citrullinated peptide (anti-CCP) are found in chronic hepatitis C virus (HCV) infection...
  14. pmc Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation
    Jessica Wagoner
    Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e16464. 2011
    ..These data underscore the differences and similarities between the intravenous and oral formulations of silibinin, which could influence the clinical effects of this mixture on patients with chronic liver diseases...
  15. ncbi request reprint Hepatitis C virus activation in HIV-infected patients initiating highly active antiretroviral therapy
    H Nina Kim
    Department of Medicine, University of Washington, Seattle, Washington 98104, USA
    AIDS Patient Care STDS 21:718-23. 2007
    ..These observations suggest that flares of hepatitis C in the setting of the immune reconstitution inflammatory syndrome can occur even in those patients who have undetectable serum HCV levels prior to HAART initiation...
  16. pmc Strengths and limitations of commercial tests for hepatitis C virus RNA quantification
    Chihiro Morishima
    Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA
    J Clin Microbiol 42:421-5. 2004
    ..Dilution prior to assay minimally decreased the reproducibility of the Monitor assay, leading to the recommendation for all specimens to be diluted 1:100 prior to testing by this assay...
  17. ncbi request reprint Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study
    Karen F Murray
    Hepatobiliary Program, Division of Gastroenterology and Nutrition, Department of Pediatrics, Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
    Pediatrics 111:153-7. 2003
    ..The purpose of this study was to determine the prevalence of HCV and high-risk behaviors in a population of incarcerated youths...
  18. ncbi request reprint Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 5:245-54. 2007
    ....
  19. ncbi request reprint Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
    Gastroenterology 126:1015-23; discussion 947. 2004
    ..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy...
  20. ncbi request reprint Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders
    William M Lee
    Control Clin Trials 25:472-92. 2004
    ..The protocol changes enhanced enrollment while upholding the original goals of the study and its integrity...
  21. ncbi request reprint Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C
    Alan Lee Rothman
    Center for Infectious Disease and Vaccine Research and Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
    Hepatology 41:617-25. 2005
    ....
  22. ncbi request reprint Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48210, USA
    Hepatology 42:282-92. 2005
    ..In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC...
  23. doi request reprint Antiviral effects of silymarin against hepatitis C: the jury is still out
    Stephen J Polyak
    Hepatology 48:345-6. 2008
  24. doi request reprint Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C
    Karen L Lindsay
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Clin Gastroenterol Hepatol 6:234-41. 2008
    ..Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression...
  25. ncbi request reprint Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial
    Gregory T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
    Hepatology 44:1675-84. 2006
    ..In conclusion, disease severity is a major independent determinant of rate of SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize antiviral therapy in these "difficult-to-cure" patients...
  26. ncbi request reprint Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C
    Herbert L Bonkovsky
    Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA
    Gastroenterology 131:1440-51. 2006
    ....
  27. pmc Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity
    April Bingham
    From Office of Clinical Research, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, Maryland 20892 1301, USA
    Medicine (Baltimore) 87:70-86. 2008
    ..Further study is warranted to investigate the pathogenesis of acquired LD in patients with DM...

Research Grants1

  1. T Cell Immunity & Liver Fibrosis in HCV/HIV Coinfection
    Chihiro Morishima; Fiscal Year: 2003
    ..Finally, we will test the hypotheses that HCV/HIV coinfected subjects treated with HAART will demonstrate improved HCV-specific CD4+ T cell function that is not fibrogenic, and is sequestered to the liver. ..